Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias.

Padovan-Neto FE, Patterson S, F Voelkner NM, Altwal F, Beverley JA, West AR, Steiner H.

Mol Neurobiol. 2019 Aug 29. doi: 10.1007/s12035-019-01739-x. [Epub ahead of print]

PMID:
31468338
2.

Age- and sex-related changes in cortical and striatal nitric oxide synthase in the Q175 mouse model of Huntington's disease.

Padovan-Neto FE, Jurkowski L, Murray C, Stutzmann GE, Kwan M, Ghavami A, Beaumont V, Park LC, West AR.

Nitric Oxide. 2019 Feb 1;83:40-50. doi: 10.1016/j.niox.2018.12.002. Epub 2018 Dec 5.

PMID:
30528913
3.

Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.

Bariotto-Dos-Santos K, Padovan-Neto FE, Bortolanza M, Dos-Santos-Pereira M, Raisman-Vozari R, Tumas V, Del Bel E.

Eur J Neurosci. 2019 Mar;49(6):869-882. doi: 10.1111/ejn.14079. Epub 2018 Sep 25.

PMID:
30022547
4.
5.

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Padovan-Neto FE, Chakroborty S, Ward KM, Harms JF, Beltran J, Kwan M, Ghavami A, Häggkvist J, Tóth M, Halldin C, Varrone A, Schaab C, Dybowski JN, Elschenbroich S, Lehtimäki K, Heikkinen T, Park L, Rosinski J, Mrzljak L, Lavery D, West AR, Schmidt CJ, Zaleska MM, Munoz-Sanjuan I.

Neuron. 2016 Dec 21;92(6):1220-1237. doi: 10.1016/j.neuron.2016.10.064. Epub 2016 Dec 1.

6.

Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?

Bortolanza M, Padovan-Neto FE, Cavalcanti-Kiwiatkoski R, Dos Santos-Pereira M, Mitkovski M, Raisman-Vozari R, Del-Bel E.

Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672). pii: 20140190. doi: 10.1098/rstb.2014.0190.

7.

Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Padovan-Neto FE, Sammut S, Chakroborty S, Dec AM, Threlfell S, Campbell PW, Mudrakola V, Harms JF, Schmidt CJ, West AR.

J Neurosci. 2015 Apr 8;35(14):5781-91. doi: 10.1523/JNEUROSCI.1238-14.2015.

8.

Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.

Issy AC, Padovan-Neto FE, Lazzarini M, Bortolanza M, Del-Bel E.

Life Sci. 2015 Mar 15;125:71-8. doi: 10.1016/j.lfs.2015.01.022. Epub 2015 Feb 12. No abstract available.

9.

Nitric oxide, a new player in L-DOPA-induced dyskinesia?

Del-Bel E, Padovan-Neto FE, Bortolanza M, Tumas V, Aguiar AS Jr, Raisman-Vozari R, Prediger RD.

Front Biosci (Elite Ed). 2015 Jan 1;7:168-92. Review.

PMID:
25553372
10.

Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.

Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, da-Silva CA, Mitkovski M, Raisman-Vozari R, Del-Bel E.

Neurobiol Dis. 2015 Jan;73:377-87. doi: 10.1016/j.nbd.2014.10.017. Epub 2014 Oct 30.

PMID:
25447229
11.

Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.

Padovan-Neto FE, Cavalcanti-Kiwiatkoviski R, Carolino RO, Anselmo-Franci J, Del Bel E.

Neuropharmacology. 2015 Feb;89:87-99. doi: 10.1016/j.neuropharm.2014.08.019. Epub 2014 Sep 4.

PMID:
25196732
12.

Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Del-Bel E, Padovan-Neto FE, Szawka RE, da-Silva CA, Raisman-Vozari R, Anselmo-Franci J, Romano-Dutra AC, Guimaraes FS.

Neurotox Res. 2014 Jan;25(1):33-44. doi: 10.1007/s12640-013-9406-3. Epub 2013 Jun 27.

PMID:
23807548
13.

Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.

Padovan-Neto FE, Ferreira NR, de Oliveira-Tavares D, de Aguiar D, da Silva CA, Raisman-Vozari R, Del Bel E.

Neurosci Lett. 2013 Apr 29;541:126-31. doi: 10.1016/j.neulet.2013.02.015. Epub 2013 Feb 18.

14.

Investigations into Potential Extrasynaptic Communication between the Dopaminergic and Nitrergic Systems.

Mitkovski M, Padovan-Neto FE, Raisman-Vozari R, Ginestet L, da-Silva CA, Del-Bel EA.

Front Physiol. 2012 Sep 25;3:372. doi: 10.3389/fphys.2012.00372. eCollection 2012.

15.

Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.

Padovan-Neto FE, Echeverry MB, Chiavegatto S, Del-Bel E.

Front Syst Neurosci. 2011 Jun 10;5:40. doi: 10.3389/fnsys.2011.00040. eCollection 2011.

16.

Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.

Del-Bel E, Padovan-Neto FE, Raisman-Vozari R, Lazzarini M.

Curr Pharm Des. 2011;17(5):471-88. Review.

PMID:
21375483
17.

Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.

Novaretti N, Padovan-Neto FE, Tumas V, da-Silva CA, Del Bel EA.

Braz J Med Biol Res. 2010 Nov;43(11):1047-53. Epub 2010 Oct 14.

18.

Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.

Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA.

Neuroscience. 2009 Mar 31;159(3):927-35. doi: 10.1016/j.neuroscience.2009.01.034. Epub 2009 Jan 23.

PMID:
19302833
19.

Role of nitric oxide on motor behavior.

Del Bel EA, Guimarães FS, Bermúdez-Echeverry M, Gomes MZ, Schiaveto-de-souza A, Padovan-Neto FE, Tumas V, Barion-Cavalcanti AP, Lazzarini M, Nucci-da-Silva LP, de Paula-Souza D.

Cell Mol Neurobiol. 2005 Mar;25(2):371-92. Review.

PMID:
16047547

Supplemental Content

Loading ...
Support Center